During Thursday night's Lightning Round one caller inquired about Sarepta Therapeutics Inc. (SRPT) : "I think they're brilliant. I think the doubters are wrong," Jim Cramer replied.
Let's check out the charts and indicators.
In the daily bar chart of SRPT, below, we can see an "interesting pattern." SRPT has been in a long sideways consolidation pattern, but look closer. Draw an imaginary line across $120 or $110 -- notice all the dips into that area? Now imagine a line across $155 or so. There are only a few tests of that line. The sense I get from this pattern is that SRPT has been bought a lot more than sold.
The moving averages are little help in the analysis. The On-Balance-Volume (OBV) line has been uneven but does show a rising pattern from April. The Moving Average Convergence Divergence (MACD) oscillator is above the zero line and rising.
In the three-year weekly bar chart of SRPT, below, we can see an impressive rise from around $30 back in 2016/2017 to over $160 in 2018. This rally has been followed by a large sideways consolidation pattern. SRPT is above the bottoming 40-week moving average line.
The weekly OBV line has held relatively stable during the sideways trend suggesting that investors did not liquidate positions. The weekly MACD oscillator has just turned up above the zero line for an outright go long signal.
In this Point and Figure chart of SRPT, below, we can see an upside price target of $177.
Bottom-line strategy: SRPT looks ready for an upside breakout. Traders could go long at current levels risking a close below $140. The $175 area is our first price target.
